Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA)
Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory
Multiple Myeloma (RRMM).
Phase:
Phase 1
Details
Lead Sponsor:
Thomas Martin, MD
Collaborators:
Actavis Inc. Eugia Pharma Specialities Limited University of California, Davis